CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Encoded closes $275M Series F for Dravet syndrome drug

Positive
AI Analysis

Summary

Encoded Therapeutics closed a $275 million Series F funding round led by GV to advance its precision genetic medicine approach for Dravet syndrome. The round also included participation from an undisclosed healthcare investor.

Importance:6/10
Sentiment:
0.70
fundraisingSeries Fprecision genetic medicineDravet syndrome
Related Companies

Read the original article

Published by Endpoints News on September 9, 2026 5:47 PM

Read Original